Back to results
US 10,328,119 B2Granted
Lipoprotein complexes and manufacturing and uses thereof
AssigneeCerenis Therapeutics Holding SA
InventorsJean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
Claims25
A population of lipoprotein complexes, each comprising
- (a) a lipid fraction consisting of a sphingomyelin and, optionally, 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)](DPPG);
- and
- (b) an apolipoprotein fraction consisting essentially of an Apolipoprotein A-I (“ApoA-I”);
- wherein
- (i) at least 95% by weight of the apolipoprotein in the population is in complexed form;
- (ii) at least 95% by weight of the lipid in the population is in complexed form;
- (iii) at least 95% of the population is in a single peak in a gel permeation chromatogram;
- (iv) the population has an apolipoprotein fraction-to-phospholipid fraction ratio of 1:2.7 by weight;
- and
- (v) the weight ratio of the sphingomyelin to DPPG, when present, is 97:3.
7 more elements
Dependencies are inferred from the claim text.